FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029265449> ?p ?o ?g. }

• W2029265449 endingPage "1031" @default.
• W2029265449 startingPage "1027" @default.
• W2029265449 abstract "Background Tyrosine kinase inhibitors (TKI) improve the outcome of patients with advanced gastrointestinal stromal tumour (GIST), but treatment failure is frequent, and prognosis then bleak. Smaller trials in this setting suggested activity for sorafenib, a multikinase inhibitor of receptor tyrosine kinases and RAF serine/threonine kinases. Patients and methods We retrospectively evaluated the efficacy of sorafenib, starting dose 400 mg twice daily, in a large community-based cohort of 124 patients treated in 12 European and one United States (U.S.) cancer centre. All but one patient had a WHO performance score 0–2. All had failed both imatinib and sunitinib, 68 patients nilotinib and 26 had failed investigational therapy, too. Results Twelve (10%) patients responded to sorafenib and 70 (57%) patients achieved disease stabilisation. Sorafenib was moderately tolerated, and toxicity reported in 56% of the patients. Rash, hand-foot-syndrome and diarrhea occurred frequently. Sorafenib dosage was reduced in a third of patients, but this did not have an impact on progression-free survival (PFS) (p = 0.15). Median PFS was 6.4 months (95% confidence interval [CI], 4.6–8.0 months) and median overall survival (OS) 13.5 months (95% CI, 10.0–21.0 months). Patients with a good performance status and those who responded to sorafenib had a significant better PFS. Conclusion We conclude that sorafenib is active in GIST resistant to imatinib, sunitinib and nilotinib. These results warrant further investigation of sorafenib or similar molecules in GIST." @default.
• W2029265449 created "2016-06-24" @default.
• W2029265449 creator A5004418792 @default.
• W2029265449 creator A5025935523 @default.
• W2029265449 creator A5031540987 @default.
• W2029265449 creator A5038723818 @default.
• W2029265449 creator A5039207289 @default.
• W2029265449 creator A5042202815 @default.
• W2029265449 creator A5046968710 @default.
• W2029265449 creator A5047539898 @default.
• W2029265449 creator A5065856111 @default.
• W2029265449 creator A5074975947 @default.
• W2029265449 creator A5090618504 @default.
• W2029265449 date "2013-03-01" @default.
• W2029265449 modified "2023-10-18" @default.
• W2029265449 title "Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis" @default.
• W2029265449 cites W1990478235 @default.
• W2029265449 cites W2012887758 @default.
• W2029265449 cites W2019607817 @default.
• W2029265449 cites W2052471444 @default.
• W2029265449 cites W2080924817 @default.
• W2029265449 cites W2085009612 @default.
• W2029265449 cites W2106501766 @default.
• W2029265449 cites W2126042521 @default.
• W2029265449 cites W2129093214 @default.
• W2029265449 cites W2156182078 @default.
• W2029265449 cites W2487815795 @default.
• W2029265449 cites W4293241248 @default.
• W2029265449 doi "https://doi.org/10.1016/j.ejca.2012.10.009" @default.
• W2029265449 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23140824" @default.
• W2029265449 hasPublicationYear "2013" @default.
• W2029265449 type Work @default.
• W2029265449 sameAs 2029265449 @default.
• W2029265449 citedByCount "61" @default.
• W2029265449 countsByYear W20292654492013 @default.
• W2029265449 countsByYear W20292654492014 @default.
• W2029265449 countsByYear W20292654492015 @default.
• W2029265449 countsByYear W20292654492016 @default.
• W2029265449 countsByYear W20292654492017 @default.
• W2029265449 countsByYear W20292654492018 @default.
• W2029265449 countsByYear W20292654492019 @default.
• W2029265449 countsByYear W20292654492020 @default.
• W2029265449 countsByYear W20292654492021 @default.
• W2029265449 countsByYear W20292654492022 @default.
• W2029265449 countsByYear W20292654492023 @default.
• W2029265449 crossrefType "journal-article" @default.
• W2029265449 hasAuthorship W2029265449A5004418792 @default.
• W2029265449 hasAuthorship W2029265449A5025935523 @default.
• W2029265449 hasAuthorship W2029265449A5031540987 @default.
• W2029265449 hasAuthorship W2029265449A5038723818 @default.
• W2029265449 hasAuthorship W2029265449A5039207289 @default.
• W2029265449 hasAuthorship W2029265449A5042202815 @default.
• W2029265449 hasAuthorship W2029265449A5046968710 @default.
• W2029265449 hasAuthorship W2029265449A5047539898 @default.
• W2029265449 hasAuthorship W2029265449A5065856111 @default.
• W2029265449 hasAuthorship W2029265449A5074975947 @default.
• W2029265449 hasAuthorship W2029265449A5090618504 @default.
• W2029265449 hasConcept C121608353 @default.
• W2029265449 hasConcept C126322002 @default.
• W2029265449 hasConcept C141071460 @default.
• W2029265449 hasConcept C143998085 @default.
• W2029265449 hasConcept C16930146 @default.
• W2029265449 hasConcept C2775922572 @default.
• W2029265449 hasConcept C2777413986 @default.
• W2029265449 hasConcept C2777583451 @default.
• W2029265449 hasConcept C2778019345 @default.
• W2029265449 hasConcept C2778570526 @default.
• W2029265449 hasConcept C2778695046 @default.
• W2029265449 hasConcept C2778729363 @default.
• W2029265449 hasConcept C2778820342 @default.
• W2029265449 hasConcept C2779490328 @default.
• W2029265449 hasConcept C2779536868 @default.
• W2029265449 hasConcept C71924100 @default.
• W2029265449 hasConcept C90924648 @default.
• W2029265449 hasConcept C98274493 @default.
• W2029265449 hasConceptScore W2029265449C121608353 @default.
• W2029265449 hasConceptScore W2029265449C126322002 @default.
• W2029265449 hasConceptScore W2029265449C141071460 @default.
• W2029265449 hasConceptScore W2029265449C143998085 @default.
• W2029265449 hasConceptScore W2029265449C16930146 @default.
• W2029265449 hasConceptScore W2029265449C2775922572 @default.
• W2029265449 hasConceptScore W2029265449C2777413986 @default.
• W2029265449 hasConceptScore W2029265449C2777583451 @default.
• W2029265449 hasConceptScore W2029265449C2778019345 @default.
• W2029265449 hasConceptScore W2029265449C2778570526 @default.
• W2029265449 hasConceptScore W2029265449C2778695046 @default.
• W2029265449 hasConceptScore W2029265449C2778729363 @default.
• W2029265449 hasConceptScore W2029265449C2778820342 @default.
• W2029265449 hasConceptScore W2029265449C2779490328 @default.
• W2029265449 hasConceptScore W2029265449C2779536868 @default.
• W2029265449 hasConceptScore W2029265449C71924100 @default.
• W2029265449 hasConceptScore W2029265449C90924648 @default.
• W2029265449 hasConceptScore W2029265449C98274493 @default.
• W2029265449 hasIssue "5" @default.
• W2029265449 hasLocation W20292654491 @default.
• W2029265449 hasLocation W20292654492 @default.
• W2029265449 hasOpenAccess W2029265449 @default.
• W2029265449 hasPrimaryLocation W20292654491 @default.

• next